Pacylex presented its exciting anti-cancer story on January 7, 2019, at the 2019 Biotech Showcase™, an investor conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. http://events.ebdgroup.com/bts/core/participating-companies2019.php Biotech Showcase (Jan 6-9, 2019) is a major biotech investment conference held annually in San Francisco alongside the JP Morgan Healthcare conference, the largest life science financing gathering annually. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year.
While at Biotech Showcase, CEO Michael Weickert, PhD, was also interviewed about the company and its lead product. In the presentation and interview, Dr. Weickert reported animal results demonstrating efficacy of PCLX-001 against various leukemias and lymphomas as well as against solid tumor cancers. The interview can be viewed here: https://www.proactiveinvestors.co.uk/companies/stocktube/11818/pacylex-pharmaceuticals-ceo-says-its-drug-can-eradicate-cancers-in-5-doses-11818.html